Furthermore, from 2018 to 2020, there was an increase of 7.0% in overweight and obesity cases in PwCF (CFF, 2019;CFF, 2021), highlighting the acceleration in recent years within this population, coinciding with increases in the use of CFTR modulator therapy (Solomon & Mallory, 2021). Here, CFTR is linked to obesity due to melanocortin 4 receptor deficiency.